The updated version of the "Patent Examination Guidelines" issued by China National Intellectual Property Administration (CNIPA) took effect on February 1, 2020, and the guidelines addressed prominent issues in the artificial intelligence (AI) field. In addition, this June (2021), Mainland China will promulgate the fourth amendment to the Patent Law, introducing patent term extension for drugs and an early patent dispute resolution mechanism.

To help Taiwanese businessmen and domestic entrepreneurs better understand the recent changes in China IP laws, TIPO subsidized Chinese National Federation of Industries (CNFI) to host the “ Seminar on AI with High Patent Value in Mainland China “ and “Seminar for the Opportunities and Challenges to Pharmaceutical Patents in Mainland China” on May 25 and June 4 respectively. Patent attorneys and experts in the AI and pharmaceutical industries from Mainland China are invited to conduct in-depth analysis and discussion on how new amendments will impact the AI and pharmaceutical industries. Welcome all to participate in these two online seminars.

• Publish Date : 2021-05-24
• Update : 2021-05-24
• Organization : International Legal Affairs Office
• Visitors : 460